Ann Oncol 2015; 26: 2125–2132 (doi: 10.1093/annonc/mdv310)
In the original manuscript, there were some errors.
The corrected paragraph and Figure 3 legend are as below.
Figure 3.
Representative cases. (A) (1) Multiply relapsed tumor: 20-year-old male, embryonal carcinoma with retroperitoneal (B) and hepatic/mediastinal/cervical metastases, HCG 123 227→ bleomycin/etoposide/cisplatin (BEP) × 4 → (2) HCG plateau →(3) 1st progression (PD)→paclitaxel/ifosfamide/cisplatin (TIP) × 2 → (4) 2nd PD → actinomycin-D/cyclophosphamide/etoposide (ACE) → (6) 3rd PD → TIP #3 → cytapheresis → (7) HDC #1 in 4th PD → (8) HDC #2 in complete remission (CR) → (9) retroperitoneal lymph node dissection (RPLND) (C) + orchiectomy (pathology: necrosis). He remains in CR 4 years after HDC #1. (D) Refractory metastatic primary mediastinal tumor: (1) 50-year-old male, acute presentation with mediastinal mass (E), multiple hemorrhagic brain (F) and lung metastases, HCG 76 227 → Urgent cisplatin/etoposide → (2) Etoposide/ifosfamide/cisplatin (VIP) → (3) HCG plateau → change to cisplatin/cyclophosphamide/doxorubicin → (4) PD → change to TIP → (5) gammaknife of three brain lesions → cytapheresis → (6) HDC #1 → (7) HDC #2 → (8) surgery of residual mediastinal and lung lesions (G) (pathology: necrosis). He remains in CR 3 years after HDC #1.
results
patient enrollment
We enrolled 43 male patients between May 2008 and August 2014, pretreated with a median 4 (2–9) regimens (Table 2). Two female patients enrolled are not included in this analysis.
Twenty patients had absolute cisplatin refractory disease (defined as PD as best response), 17 refractory disease (relapse/PD within 4 weeks) disease and 6 had cisplatin-sensitive disease.
Disease was nonresponsive in 24 patients (22 PD, 2 SD), and responsive in 19 patients (8 PRm+, 7 PRm−, 4 CR—one surgical—) right before HDC (individual treatment histories in supplementary Table S1, available at Annals of Oncology online).